Familial hyperaldosteronism type II (FH-II) is an inherited form of hyperaldosteronism associated with hypertension in most patients. The mutations that cause FH-II are unknown, but linkage analysis has mapped them to chromosome 7p22. As FH-II is clinically indistinguishable from sporadic primary aldosteronism, a common and treatable condition, unravelling the cause of FH-II has important implications for these sporadic cases. To investigate whether FH-II is caused by large deletions or insertions, we examined the virtual karyotype of four pairs of affected and unaffected individuals using highdensity bead chips. We also sequenced the coding regions of five 7p22 candidate genes that were prioritized because of their putative role in cell growth. We found no evidence of single-nucleotide polymorphism (SNP) copy number variation between pairs, and from the widest gap on the chip, chromosome 7p22 deletions or insertions exceeding B50 kb in these pedigrees can be excluded. We found 15 SNPs (two of which were novel), but none of them were non-synonymous and segregated with the disease in the FH-II pedigrees. We have been able to exclude large genomic deletions or insertions at 7p22 and refine the candidate gene list for this locus, but the mutations causing FH-II remain elusive.
Introduction
Current estimates suggest that as many as 5-10% of patients labelled as having essential hypertension may actually have primary aldosteronism (PAL). 1 An aldosterone-renin ratio greater than 25 suggests the possibility of PAL, 2 which is confirmed by demonstrating that aldosterone is not suppressible despite suppression of renin by salt loading. Elevated levels of aldosterone, associated with adrenocortical hyperplasia or aldosterone-producing adenoma, usually result in suppressed renin levels in all cases and hypertension in most cases.
Most PAL cases have been regarded as sporadic, but hypertensive relatives are not routinely tested; hence, a familial syndrome cannot usually be excluded. There are three known familial conditions involving PAL, the most common of which is familial hyperaldosteronism type II (FH-II, OMIM #605635). The molecular basis of FH-II is unknown and affected individuals do not have the mutation known to cause the related condition, familial hyperaldosteronism type I (FHI).
2 FH-II is clinically identical to sporadic PAL, and it is reasonable to hypothesize that a proportion of sporadic cases represent undetected FH-II. Hence, establishing the molecular basis for FH-II should provide an important and rapid genetic screening method for these patients, as well as provide a better understanding of the pathophysiology of PAL.
FH-II was first described in 1991. 3 In 2000, the disease gene was mapped to a 5 Mb region of chromosome 7p22 by linkage analysis (logarithm of odds, score 3.26). 4 Subsequent studies confirmed the locus (logarithm of odds, 4.61) and refined it to an approximately 3 Mb region. 5 Involvement of several candidate genes either within or close to this region has been excluded by sequencing analysis. 6, 7 It is noteworthy that this same locus may be generally more important for aldosterone secretion and for the aldosterone-renin ratio. The log aldosterone-renin ratio is normally distributed in the general population, highly heritable and in a normotensive cohort linked to the same 7p22 locus. 8 The linkage was much weaker after correction for medications such as angiotensin-converting enzyme inhibitors, but the coincidence of the two loci is intriguing.
To investigate further the molecular basis for FH-II, we used a dense single-nucleotide polymorphism (SNP) microarray to determine genomic deletions or insertions around the 7p22 interval. We also sequenced five selected 7p22 genes in affected individuals in order to identify any mutations that could be the cause of FH-II. This region contains around 40 genes, none of which are known to be directly involved in aldosterone synthesis. We elected to prioritize for sequencing the five genes that we thought were most likely to be involved in FH-II pathogenesis on the basis of existing knowledge of their function. We selected genes involved in transcription, protein regulation or control of cell division, because of the adrenal hyperplasia and/or tumour formation associated with FH-II. FOXK1 (forkhead box K1) is a transcriptional regulator; 9 FSCN1 (fascin homologue 1, actin-bundling protein) is upregulated in some cancer cell lines; 10 RNF216 (ring finger protein 216) has a role in ubiquitination;
11 EIF2AK1 (eukaryotic translation initiation factor 2-a-kinase 1) downregulates certain proteins in response to stress; 12 RAC1 (ras-related C3 botulinum toxin substrate 1) has a role in cell division. 13 
Materials and methods

SNP virtual karyotyping
Informed consent was obtained from all participants and the study was approved by the institutional ethics review committee.
Genomic deoxyribonucleic acid (DNA) from four pairs of participants was analysed using the Human CNV370-Duo BeadChip (Illumina, Saffron Walden, UK). This chip contains over 370 000 SNPs to investigate SNP genotype and copy number across the entire genome. Around 440 of these are found within our 3 Mb 7p22 region of interest. The largest gap between SNPs within this region is 48.4 kb, and the mean size of gaps between SNPs is 6.6 kb. See Supplementary Table S1 for full details of SNPs covered by the chip.
Each participant pair consisted of one affected and one unaffected individual from one of four pedigrees linked to 7p22, previously described in detail. 5 The unaffected participant of pair three was reclassified as having uncertain affectation status during the course of this study. This work was carried out by the University of Cambridge Centre for Microarray Resources. Fluorescence data were analysed using Illumina BeadStudio 3.1.3.0 and additional software modules: Genotyping 3.2.23 and Genome Viewer 3.2.7 (Illumina, Saffron Walden, UK). The log 2 (Rsub/Rref) score and copy number for each copy number variant on the SNP microarray were estimated, and the data observed across each chromosome using the Illumina software.
To calculate copy number variation estimates, we used an algorithm provided by Beadstudio to compare each log 2 (Rsub/Rref) score with the expected frequency of the allele, allowing for normal variation in the range of values.
Whole-genome amplification
The Illustra GenomiPhi V2 DNA Amplification Kit (GE Healthcare, Buckinghamshire, UK) was used according to manufacturer's instructions to increase the inadequate quantities of genomic DNA from participants. This system was selected as it is designed to minimize amplification bias, and uses a DNA polymerase with 3 0 -5 0 proofreading exonuclease activity to increase accuracy.
Polymerase chain reaction (PCR)
Specific primer pairs were designed to flank exons and exon-intron boundaries, using Primer3 and primer-BLAST.
14 See Supplementary Table S2 for primer pairs. PCR was initially carried out using highly purified control DNA (Bioline, London, UK) to optimize the cycling conditions for each primer pair. This was repeated along with at least two affected FH-II samples from previously described pedigrees 5 in which linkage to the same 7p22 locus had been confirmed, and with a water control. The successful detection of disease mutations in Mendelian disorders has been widely reported with similar numbers (p4) of affected individuals. [15] [16] [17] PCRs were typically carried out using 2 Â AmpliTaq Gold Fast PCR Master Mix (Applied Biosystems, Warrington, UK), 0.5 mmol l À1 each desalted primer (Invitrogen, Paisley, UK), 20 ng template DNA and water. The cycling conditions suggested by the manufacturer were used as a starting point for most primer pairs.
Successful amplification was confirmed by visualization of the products using standard agarose gel electrophoresis. The product was purified using a PCR purification kit (Qiagen, Crawley, UK) and the eluted DNA was quantified using a Nanodrop ND-1000 Spectrophotometer (Thermo Fisher Scientific, Basingstoke, UK).
Sequencing and analysis
A volume of 50 ng of each purified PCR product and 3 pmol of one primer were added to 8 ml Quickstart sequencing PCR mastermix (Beckman Coulter, High Wycombe, UK) and water. Typically, one 5 0 (forward) and one 3 0 (reverse) sequencing reaction were run for each PCR product. The PCR reactions were amplified using the cycling conditions suggested by the manufacturer. The products were purified by ethanol precipitation, transferred into 96-well plates and analysed on a CEQ 8000 Genetic Analysis System (Beckman Coulter). The resulting sequence was aligned with the expected wild-type sequence according to the GenBank sequence database (GRCh37 assembly), using BioEdit Sequence Alignment Editor 7.0.9.0. 18 The analysed data were also visually examined to identify any heterozygous mutations.
Results
Genome-wide SNP genotyping
We could find no evidence of deletions or insertions in the genomes of subjects with FH-II across the 3 Mb interval of interest, nor elsewhere in the genome (data not shown), at the level of resolution possible with the CNV370-Duo Beadchip. The copy number variation estimates and genomic locations of the 440 7p22 SNPs investigated for participant pair 1 are shown in Figure 1 .
Candidate gene sequencing
During the course of sequencing of the five candidate genes FOXK1, FSCN1, RNF216, EIF2AK1 and RAC1, 15 polymorphisms were identified that differ in sequence from the consensus sequence in GenBank database (GRCh37 assembly) ( Table 1) . See Supplementary Table S3 for individuals' genotypes. Fourteen of the polymorphisms are singlebase substitutions and one is a single-base deletion. Eleven are intronic and the remaining four are synonymous (they do not alter the amino acid residue in the protein). There are population data for 11 of the SNPs. None of the genotypes that we observed in these 11 SNPs occur at a frequency of below 12% in European populations. 19 We identified two novel SNPs. These have been submitted to the single-nucleotide polymorphism database and accession numbers have been allocated (ss196000732 and ss196000733). Importantly, genotypes segregate with the disease in only three of the SNPs. None of these three are non-synonymous or affect a splice site. The segregation of these three SNPs is probably a coincidence because of the small sample size.
Discussion
Given that no copy number variation was identified between related participants in the SNPs that were tested, and that the largest gap between SNPs covered on the array is 48.4 kb, we can confidently exclude a genomic deletion that is much larger than #145260) . 20 Nevertheless, the WNK1 deletions are unusual, with monogenic syndromes more frequently caused by small non-synonymous mutations. 21 The results of our virtual karyotyping support the hypothesis that FH-II is caused by such a mutation.
We set two criteria that a polymorphism identified through sequencing had to meet for it to be considered as the causative mutation. The first criterion is that it must segregate with the disease in at least six affected and six related unaffected individuals. Second, it must be non-synonymous, or must affect a splice site. These criteria are commonly used for such studies, and to our knowledge there are no reported cases of Mendelian disorders caused by synonymous substitutions (other than where they affect splice sites). An acceptable frequency for a putative causal mutation is problematic, because the possibility exists that a significant minority of PAL patients may carry it. Hence, a frequency of up to 2% in the general population is conceivable, and it may have already been reported. Nevertheless, none of the SNPs we identified met our criteria, and all of the genotypes that we observed in affected patients occur at a frequency of well above 2% (in cases in which population data are available). Therefore, on the basis of these criteria, we can exclude the genes FOXK1, FSCN1, RNF216, EIF2AK1 and RAC1 as candidates for causing FH-II.
We have been able to exclude large genomic deletions or insertions as a cause of FH-II, and refine the candidate gene list, but the diseasecausing mutations remain elusive. Further work to identify them is needed and the use of nextgeneration sequencing is probably the most efficient method of detecting causative FH-II mutations within the remaining unprobed genes in the 7p22 region. In fact, as proof of this approach, nextgeneration sequencing has been recently used to uncover new mutations in rare Mendelian diseases. 15, 16, 22, 23 The identification of the gene defects causing FH-II could have an important impact on sporadic cases of PAL. The two conditions have indistinguishable clinical presentations; therefore, it is not unreasonable to suppose that the mechanisms of causation of these diseases may be similar. Hence, the identification of mutations causing FH-II may be relevant to the larger group of patients who suffer from PAL in at least two ways. First, PAL is a specifically treatable form of hypertension and the possibility of a rapid genetic diagnosis for PAL patients is very attractive; currently, many PAL patients are misdiagnosed as having resistant essential hypertension and, as a result, inappropriately managed. Second, it may elucidate the (common) pathophysiology behind these conditions. None of the genes under the 7p22 FH-II locus are currently known to be involved in regulating the synthesis or release of aldosterone. This suggests that the molecular basis for FH-II and sporadic PAL involves a novel mechanism or pathway within the adrenal gland orchestrated by the causative gene under the 7p22 locus.
